A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs GBR 1302 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Glenmark Pharmaceuticals S.A.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 28 Apr 2017 Planned number of patients changed from 30 to 60.
- 28 Apr 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.